Articles from Transcripta Bio

Transcripta Bio, an AI-powered drug discovery company focused on neurological and neuromuscular disease, and Synfini, Inc., an agile AI foundry for small-molecule drug discovery, today announced results from a research collaboration that has produced a validated-quality lead candidate directed at MSH3, a gene increasingly understood to drive the somatic repeat expansion that paces the progression of Huntington’s disease. The companies reached the milestone in a matter of weeks.

Transcripta Bio, an AI-powered drug discovery company focused on neurological and neuromuscular diseases, today announced additions to its Scientific Advisory Board (SAB). The SAB includes leaders with expertise in human genetics, transcriptomic biology, clinical drug development, and neuromuscular clinical trial design.

Transcripta Bio, an AI-powered drug discovery company focused on neurological and neuromuscular diseases, today announced it has raised $24 million since its Series A to advance IND-enabling studies across its portfolio and support clinical preparation in its Autism Spectrum Disorder (ASD) and Facioscapulohumeral Muscular Dystrophy (FSHD) programs. Mayo Clinic and Omnimed join existing investors JAZZ Venture Partners, BlueYard Capital, and a group of life sciences family offices as the company advances its pipeline toward human clinical trials. The company's pipeline spans four programs across Myotonic Dystrophy, FSHD, ASD, and Huntington's Disease (HD).

Transcripta Bio, a platform drug development biotechnology company that is revolutionizing discovering and developing medicines at unprecedented speed, scale, and capital efficiency, has been included in the fourth-annual TIME100 Most Influential Companies list. The prestigious list spotlights companies around the world that are making an extraordinary impact and recognizes Transcripta Bio’s significant achievements in speeding drug discovery.